Although lapatinib is a HER2 inhibitor and mainly used in the BRCA HER2 + subtype, this negative correlation trend was observed in many cancer types (23 out of the 39 cancer types (30 main cancer types plus 4 BRCA subtypes, 3 LGG subtypes, and 2 THCA subtypes), P < 0.05 and NES < 0, GSEA). Here, ERBB2 is linked to cancer.